241 related articles for article (PubMed ID: 8756813)
1. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung.
Behr J; Vogelmeier C; Beinert T; Meurer M; Krombach F; König G; Fruhmann G
Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):400-6. PubMed ID: 8756813
[TBL] [Abstract][Full Text] [Related]
2. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis.
De Santis M; Bosello S; La Torre G; Capuano A; Tolusso B; Pagliari G; Pistelli R; Danza FM; Zoli A; Ferraccioli G
Respir Res; 2005 Aug; 6(1):96. PubMed ID: 16107215
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage.
Silver RM; Miller KS; Kinsella MB; Smith EA; Schabel SI
Am J Med; 1990 May; 88(5):470-6. PubMed ID: 2337105
[TBL] [Abstract][Full Text] [Related]
4. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
6. Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters.
Volpinari S; La Corte R; Bighi S; Ravenna F; Prandini N; Lo Monaco A; Trotta F
Rheumatol Int; 2011 Sep; 31(9):1183-8. PubMed ID: 20352228
[TBL] [Abstract][Full Text] [Related]
7. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
Colaci M; Sebastiani M; Giuggioli D; Manfredi A; Spagnolo P; Luppi F; Richeldi L; Ferri C
Scand J Rheumatol; 2010 Mar; 39(2):155-9. PubMed ID: 20059446
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis.
Witt C; Borges AC; John M; Fietze I; Baumann G; Krause A
Ann Rheum Dis; 1999 Oct; 58(10):635-40. PubMed ID: 10491363
[TBL] [Abstract][Full Text] [Related]
9. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis.
Clements PJ; Goldin JG; Kleerup EC; Furst DE; Elashoff RM; Tashkin DP; Roth MD
Arthritis Rheum; 2004 Jun; 50(6):1909-17. PubMed ID: 15188367
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast chemotactic response elicited by native bronchoalveolar lavage fluid from patients with fibrosing alveolitis.
Behr J; Adelmann-Grill BC; Krombach F; Beinert T; Schwaiblmair M; Fruhmann G
Thorax; 1993 Jul; 48(7):736-42. PubMed ID: 8153923
[TBL] [Abstract][Full Text] [Related]
11. Lung disease associated with progressive systemic sclerosis. Assessment of interlobar variation by bronchoalveolar lavage and comparison with noninvasive evaluation of disease activity.
Miller KS; Smith EA; Kinsella M; Schabel SI; Silver RM
Am Rev Respir Dis; 1990 Feb; 141(2):301-6. PubMed ID: 2301848
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
Kowal-Bielecka O; Kowal K; Rojewska J; Bodzenta-Lukaszyk A; Siergiejko Z; Sierakowska M; Sierakowski S
Ann Rheum Dis; 2005 Sep; 64(9):1343-6. PubMed ID: 16100339
[TBL] [Abstract][Full Text] [Related]
13. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature.
Kowal-Bielecka O; Kowal K; Highland KB; Silver RM
Semin Arthritis Rheum; 2010 Aug; 40(1):73-88. PubMed ID: 19152959
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.
Giacomelli R; Valentini G; Salsano F; Cipriani P; Sambo P; Conforti ML; Fulminis A; De Luca A; Farina G; Candela M; Generini S; De Francisci A; Tirri E; Proietti M; Bombardieri S; Gabrielli A; Tonietti G; Cerinic MM
J Rheumatol; 2002 Apr; 29(4):731-6. PubMed ID: 11950014
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease.
Kowal-Bielecka O; Distler O; Kowal K; Siergiejko Z; Chwiećko J; Sulik A; Gay RE; Łukaszyk AB; Gay S; Sierakowski S
Arthritis Rheum; 2003 Jun; 48(6):1639-46. PubMed ID: 12794832
[TBL] [Abstract][Full Text] [Related]
16. Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment.
Sahhar J; Littlejohn G; Conron M
Intern Med J; 2004 Nov; 34(11):626-38. PubMed ID: 15546457
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
Várai G; Earle L; Jimenez SA; Steiner RM; Varga J
J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
[TBL] [Abstract][Full Text] [Related]
18. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.
Beretta L; Caronni M; Raimondi M; Ponti A; Viscuso T; Origgi L; Scorza R
Clin Rheumatol; 2007 Feb; 26(2):168-72. PubMed ID: 16614793
[TBL] [Abstract][Full Text] [Related]
19. Pathogenetic and clinical significance of fibroblast activation in scleroderma lung disease.
Behr J; Adelmann-Grill BC; Hein R; Beinert T; Schwaiblmair M; Krombach F; Fruhmann G
Respiration; 1995; 62(4):209-16. PubMed ID: 8578017
[TBL] [Abstract][Full Text] [Related]
20. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
Clements PJ; Roth MD; Elashoff R; Tashkin DP; Goldin J; Silver RM; Sterz M; Seibold JR; Schraufnagel D; Simms RW; Bolster M; Wise RA; Steen V; Mayes MD; Connelly K; Metersky M; Furst DE;
Ann Rheum Dis; 2007 Dec; 66(12):1641-7. PubMed ID: 17485423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
